Skip to Content

Management of Erdafitinib, a pan-FGFR kinase inhibitor, treatment-emergent adverse events

Erdafitinib was US FDA approved for adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3/2 alterations who progressed on ≥ 1 line of prior platinum-based chemotherapy. In this MEDtalk Arlene O. Siefker-Radtke present how the treatment-emergent adverse events mostly were managed with concomitant treatment and dose modifications, so the patients could stay in treatment with the fibroblast growth factor receptor, Erdafitinib inhibitor.

Avaa artikkeli

Jos olet lääkäri, sairaanhoitaja tai muu terveydenhuollon ammattilainen, voit käyttää koko artikkelia luomalla profiilin BestPractice Nordic -sivustolle.

Back to top